Carl Icahn and the Last Crusade: The Tipline for 12 June 2023

Illumina/Grail is unpopular at the Federal Trade Commission, and perhaps, at Illumina as well. The company revealed yesterday that it has accepted the resignation of chief executive Francis deSouza, the DNA-sequencing company’s chief executive of the last five years. His tenure had been in question since activist investor Carl Icahn initiated a proxy battle for control last year, in part, over concerns with deSouza’s crusade to acquire Grail despite antitrust challenges in the US and EU.